AstraZeneca to conduct Phase II study for olaparib

Published: 2010-02-17 06:57:00

Updated: 2010-02-17 06:57:00

The battle against cancer seems to be on the verge of a major step forward. The success of a new class of drugs “PARP inhibitors” in destroying the disease points to a new direction in the development of anticancer drugs.

AstraZeneca said on February 11 that it will conduct its Phase IIa study...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK